21:36 , Jul 18, 2019 |  BC Extra  |  Company News

Mammoth stakes IP claim to CRISPR diagnostic applications

With two newly issued patents covering key CRISPR systems for diagnostic applications, Mammoth strengthens its IP position as it pushes its CRISPR-based diagnostic platform closer to the clinic. The CRISPR patent landscape hasn't been as...
22:22 , Jul 12, 2019 |  BC Extra  |  Preclinical News

July 12 Preclinical Quick Takes: Feng Zhang develops latest RNA editing platform, plus tools from David Liu and NIH

Zhang's RESCUE platform converts RNA C to U bases  Feng Zhang and colleagues at Massachusetts Institute of Technology and the Broad Institute of MIT and Harvard have developed a single base RNA editing system that...
00:25 , Jun 22, 2019 |  BC Extra  |  Financial News

Mirum, Fulcrum file for IPOs

On Friday, Mirum and Fulcrum each filed to raise up to $86.3 million in NASDAQ IPOs. Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched in November with a $120 million series A round led by New...
00:38 , Jun 21, 2019 |  BC Innovations  |  Tools & Techniques

A human CRISPR-like system adds a new approach to regulating translation

A new system modeled on CRISPR and made entirely of human proteins is the latest strategy to intervene in gene control at the RNA translation level. The technology could bring higher levels of precision and...
22:14 , Jun 14, 2019 |  BioCentury  |  Emerging Company Profile

Sherlock: Leveraging CRISPR, synthetic biology for diagnostics

By taking advantage of two hot technologies, Sherlock is developing a pair of molecular diagnostics that can be used alone or together to rapidly and accurately detect disease in a wide variety of applications. Sherlock...
21:48 , Jun 6, 2019 |  BC Innovations  |  Translation in Brief

CRISPR pioneer Zhang describes new technique to insert genes

Feng Zhang's latest study brings the gene editing field one step closer to correcting and replacing, rather than just disrupting, target genes. The challenge now will be translating the technique from prokaryotic cells to eukaryotic...
23:46 , Jun 4, 2019 |  BC Extra  |  Company News

June 4 Company Quick Takes: Lilly's Emgality gets expanded indication; plus Vimizim, Zerbaxa and more

Emgality gets U.S. approval for episodic cluster headaches  FDA approved Emgality galcanezumab-gnlm from Eli Lilly and Co. (NYSE:LLY) to treat episodic cluster headache in adults. The anti-CGRP mAb is already approved as a prophylaxis for...
23:35 , Jun 4, 2019 |  BC Extra  |  Tools & Techniques

OHSU's Mitalipov proposes path forward for germline gene editing

Germline gene editing pioneer Shoukhrat Mitalipov has weighed in on therapeutic use of the technology, writing in a Nature Medicine perspective that it should only be applied when it can convert a mutated gene to...
21:58 , May 28, 2019 |  BC Innovations  |  Translation in Brief

Liu’s new strategy could make gene editing insertions more precise

The latest study from CRISPR veteran David Liu describes a new tweak to the gene editing machinery that could better position it to correct, rather than just disrupt, gene targets. Using CRISPR to disrupt a...
19:12 , May 23, 2019 |  BC Innovations  |  Translation in Brief

Template-free CRISPR for correcting pathogenic duplications

A UMass med school team has shown how template-free CRISPR could repair pathogenic DNA duplications and identified over a hundred disease-associated mutations as targets for the new method. Author Scot Wolfe, a professor of molecular,...